Citizens analyst Jonathan Wolleben initiated coverage on Annexon (ANNX) with a 'Market Underperform' rating and a $3 price target. This new analyst coverage and negative rating could put downward pressure on ANNX shares in the short term.
Citizens analyst Jonathan Wolleben has initiated coverage on Annexon (ANNX), a biotechnology company, with a 'Market Underperform' rating and a price target of $3. This is a significant event for ANNX as new analyst coverage, especially with a negative outlook, can influence investor sentiment and stock price. The 'Underperform' rating suggests that the analyst expects ANNX to perform worse than the broader market or its sector peers. This could lead to short-term selling pressure on ANNX shares as investors react to the negative assessment. For traders, this presents a potential short-selling opportunity or a signal to avoid the stock, at least until more positive catalysts emerge or the analyst's thesis is challenged.